Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
John M. Kirkwood, MD
Sapna Patel, MD
Reimagining Lung Cancer Treatment: A Journey Through New and Emerging Therapeutics Related to the Care of Patients with Small Cell and Non-Small Cell Lung Cancer
Stephen Liu, MD
Joshua K. Sabari, MD
Susan Scott, MD
Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
HER2-Driven Strategies in Metastatic NSCLC
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Paolo A. Ascierto, MD
Hussein Tawbi, MD, PhD
Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
Chemotherapy Strategies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Eileen O’Reilly, MD
Efrat Dotan, MD
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
Fernando López-Ríos, MD, PhD
Christian Rolfo, MD, PhD
Charlie Gourley, MD, PhD
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.